Clinical trials: Neoadjuvant Treatment
Breast Cancer
Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer
We, the investigators at Baylor Breast Care Cancer, are doing this study to learn how well Taxotere makes tumors become smaller.
- Trial name
- NCT00206453
- Testing
- Taxotere
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Baylor Breast Care Center
Colon Neoplasm
Effect Analysis of Neoadjuvant Chemoradiotherapy Combined With Surgery in Laparoscope for Advanced Colon Cancer
In this study, a randomized controlled trial was conducted on advanced colon cancer patients with preoperative tumor staging T1-4/N1-2/M0 or T4/N0/M0 to determine the effectiveness of preoperative short-term radiotherapy combined…
- Trial name
- NCT05279612
- Testing
- Short-term neoadjuvant chemoradiotherapy
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Tang-Du Hospital
Prostate Cancer, Prostate Cancer Patients
177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial
The goal of this clinical trial is to explore the efficacy and safety of darolutamide combined with 177Lu-PSMA-617 in treating high-risk localized prostate cancer patients who are scheduled to undergo radical prostatectomy.
- Trial name
- IUNU-PC-123 (NCT07677566)
- Testing
- Darolutamide combined with 177Lu-PSMA-617
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Triple Negative Breast Cancer
68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)
Prospective multicenter study evaluating the prediction of histological response after neoadjuvant pembrolizumab in combination with chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patients with early-stage high-risk…
- Trial name
- FAP-IT (NCT06349512)
- Testing
- 68Ga-FAPI-46 PET/CT imaging
- Where
- 6 sites in France
- Volunteers
- 60 people
- Sponsor
- Institut Curie
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
This partially randomized phase I/II trial studies the side effects and best dose of elotuzumab and to see how well it works when given together with lenalidomide, bortezomib, and dexamethasone in treating patients with newly…
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
- Trial name
- NCT01668719
- Testing
- Bortezomib, Dexamethasone, Elotuzumab
- Where
- 417 sites in United States
- Volunteers
- 142 people
- Sponsor
- SWOG Cancer Research Network
Triple-negative Breast Cancer, HER2-positive Breast Cancer
CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC
This is a prospective, single-center, non-randomized, non-controlled observational study.
- Trial name
- NCT04457700
- Where
- China
- Volunteers
- 218 people
- Sponsor
- Peking University
Cholangiocarcinoma, Intrahepatic
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
A randomized controlled, multi-center, open, phase II clinical study is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative…
- Trial name
- NCT04506281
- Testing
- neoadjuvant treatment
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Cancer
Probiotic Supplementation During Neoadjuvant Chemoradiotherapy in Colorectal Cancer
This prospective randomized, double-blind, placebo-controlled study evaluated the effects of multistrain probiotic supplementation in patients with stage II-III colorectal cancer undergoing neoadjuvant chemoradiotherapy.
- Trial name
- NCT07863154
- Testing
- Multistrain Probiotic Formulation
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- University of Malaga
Resectable Lung Non-Small Cell Carcinoma
A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage…
- Trial name
- NCT06775275
- Testing
- Adebellizumab, Bevacizumab, Platinum-based chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Acute Myelogenous Leukemia
Differentiation Induction in Acute Myelogenous Leukemia
Hypothesis: Differentiation induction therapy in acute myelogenous leukemia (AML) can be used to achieve disease control and stabilize peripheral blood counts in patients with acute myelogenous leukemia.
- Trial name
- NCT00175812
- Testing
- all-trans retinoic acid (ATRA), Valproic acid, Theophyllin
- Where
- Norway
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Bergen
Breast Cancer
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
Patients with HER-2 positive breast cancer who have poor outcomes after endocrinotherapy and standard chemotherapy can be significantly improved by the use of anti-HER-2 monoclonal antibody trastuzumab.
- Trial name
- NCT04973319
- Testing
- Pyrotinib, Trastuzumab
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Shengjing Hospital
Colorectal Cancer
SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
To explore the safety and efficacy of neoadjuvant therapy for locally advanced rectal cancer with short course radiotherapy followed by camrelizumab combined with fluzoparib and chemotherapy
- Trial name
- NCT06516445
- Testing
- SCRT, Camrelizumab, Fluzoparib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Huazhong University of Science and Technology
Breast Cancer
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
The scope of this study is to measure the impact of MammaPrint on treatment in Hormone Receptor (HR)-positive HER2-negative breast cancer patients.
- Trial name
- IMPACt (NCT02670577)
- Where
- 17 sites in United States
- Volunteers
- 481 people
- Sponsor
- Agendia
Oral Squamous Cell Carcinoma
A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.
Given the feasibility of induction chemotherapy in oral cancer and the encouraging remission rates achieved, we explore the clinical application prospects of using tislelizumab in combination with traditional standard…
- Trial name
- B2023-153 (NCT06130007)
- Testing
- Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Xuekui Liu
Multiple Myeloma, Neoplasms
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
The purpose of this study is to see how long lenalidomide therapy can maintain or improve the disease response obtained after induction therapy that does not include lenalidomide, pomalidomide or thalidomide; and consequently…
- Conditions
- Multiple Myeloma, Neoplasms, Plasma Cells, Paraproteinemias
- Trial name
- NCT02155634
- Testing
- Lenalidomide
- Sponsor
- Celgene
Rectal Adenocarcinoma, High-Risk Cancer
NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC
To explore the efficacy and safety of adding a ketogenic diet and/or high-dose intravenous vitamin C to neoadjuvant short-course radiotherapy followed by mFOLFOX6 chemotherapy combined with serplulimab in patients with locally…
- Conditions
- Rectal Adenocarcinoma, High-Risk Cancer, MSS
- Trial name
- CRI-KEV (NCT07765667)
- Testing
- Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Bladder Cancer
Complete Local Response to Neoadjuvant Chemotherapy in Patients With Muscle Invasive Bladder Cancer Evaluated by 15O-H2O PET/MR
Treatment of localized muscle invasive bladder cancer (MIBC) is radical cystectomy. Neoadjuvant chemotherapy (NAC) improves survival.
- Trial name
- MAINTAIN (NCT04321707)
- Testing
- 15O-H2O PET/MR
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Jørgen Bjerggaard Jensen
Ovarian Epithelial Cancer
Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
Ovarian cancer is among the top five primary causes of cancer-related mortality in women. Most ovarian malignant tumours originate from epithelial cells The majority of patients typically have advanced-stage tumours at diagnosis.
- Trial name
- NCT06404671
- Testing
- Delayed interval cytoreductive surgery (DICS), Early interval cytoreductive surgery (EICS)
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Alexandria University
Gastric or Gastroesophageal Junction Adenocarcinoma
Efficacy and Safety of Intraoperative Radiotherapy Combined With Serplulimab Plus Chemotherapy Versus Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
This study evaluates the clinical efficacy and safety benefits of neoadjuvant intraoperative radiotherapy combined with immunotherapy and chemotherapy by comparing intraoperative radiotherapy plus serplulimab plus chemotherapy…
- Trial name
- NICT-IORT (NCT07870798)
- Testing
- Serplulimab, Intraoperative exploration plus intraoperative radiotherapy, Intraoperative exploration without intraoperative radiotherapy
- Volunteers
- 68 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Esophageal Squamous Cell Carcinoma (ESCC)
A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
Esophageal cancer is a high - incidence cancer type in China, characterized by high incidence, high mortality, and low survival rates.
- Trial name
- NCT06863831
- Testing
- Yishen Qutong Granules, Yishen Qutong Simulant Granules
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.